Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats

被引:8
作者
Cooper, Dustin L. [1 ]
Wood, Robert C., III [2 ]
Wyatt, Jarrett E. [2 ]
Harirforoosh, Sam [1 ]
机构
[1] E Tennessee State Univ, Gatton Coll Pharm, Dept Pharmaceut Sci, Johnson City, TN 37614 USA
[2] E Tennessee State Univ, Gatton Coll Pharm, Johnson City, TN 37614 USA
关键词
NSAIDs; Rebamipide; Pharmacokinetics; HPLC; Celecoxib; Diclofenac; GASTRIC-MUCOSAL INJURY; CYTOCHROME-P450; INVOLVEMENT; CELECOXIB; NSAIDS; ULCER;
D O I
10.1016/j.ejps.2013.12.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal and renal side effects. Rebamipide is a mucoprotective agent that reduces gastrointenstinal side effects when administered concomitantly with NSAIDs. In this study, we investigated the pharmacokinetic drug interactions of rebamipide with two selected NSAIDs, celecoxib or diclofenac. Rats were randomly divided into five groups. Two groups received placebo and three groups were administered rebamipide (30 mg/kg) orally twice daily for two days. On day 3, the animals treated with placebo received celecoxib (40 mg/kg) or diclofenac (10 mg/kg) and rats receiving rebamipide were administerd rebamipide followed by a single dose of placebo, celecoxib, or diclofenac. To investigate drug protein interactions, blank rat plasma was spiked with known concentrations of rebamipide, diclofenac plus rebamipide, or celecoxib plus rebamipide then dialyzed through a Rapid Equilibrium Dialysis device. AUC (139.70 +/- 24.97 mu g h/mL), C-max (42.99 +/- 2.98 mu g/mL), and CLoral (0.08 +/- 0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups. Treatment with rebamipide showed no significant change in pharmacokinetic parameters of celecoxib treated rats. C-max (7.80 +/- 1.22 mu g/mL), AUC (56.46 +/- 7.30 mu g h/mL), V-d/F (7.55 +/- 1.37 L/kg), and CLoral (0.58 +/- 0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide. Pharmacokinetic parameters of rebamipide plus celecoxib group were not significantly different from those of rebamipide group. Plasma protein binding was not affected by concomitant administration of another drug. These results indicate alteration of pharmacokinetic parameters of both rebamipide and diclofenac when co-administered and cannot be explained by a variation in plasma protein binding. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:28 / 34
页数:7
相关论文
共 31 条
[1]   REBAMIPIDE, NOVEL PROSTAGLANDIN-INDUCER, ACCELERATES HEALING AND REDUCES RELAPSE OF ACETIC ACID-INDUCED RAT GASTRIC-ULCER - COMPARISON WITH CIMETIDINE [J].
ARAKAWA, T ;
WATANABE, T ;
FUKUDA, T ;
YAMASAKI, K ;
KOBAYASHI, K .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (11) :2469-2472
[2]   Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity [J].
Boelsterli, UA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2003, 192 (03) :307-322
[3]   Pharmacokinetics and Bioequivalence of Two Formulations of Rebamipide 100-mg Tablets: A Randomized, Single-Dose, Two-Period, Two-Sequence Crossover Study in Healthy Korean Male Volunteers [J].
Cho, Hea-Young ;
Yoon, Hwa ;
Park, Geun-Kyeong ;
Lee, Yong-Bok .
CLINICAL THERAPEUTICS, 2009, 31 (11) :2712-2721
[4]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[5]   Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice [J].
Diao, Lei ;
Mei, Qiao ;
Xu, Jian-Ming ;
Liu, Xiao-Chang ;
Hu, Jing ;
Jin, Juan ;
Yao, Qiang ;
Chen, Mo-Li .
WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (10) :1059-1066
[6]   Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction [J].
Fang, Zhong-Ze ;
Zhang, Yan-Yan ;
Ge, Guang-Bo ;
Huo, Hong ;
Liang, Si-Cheng ;
Yang, Ling .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (02) :193-199
[7]  
Gibaldi M., 1982, Pharmacokinetics
[8]  
Green G A, 2001, Clin Cornerstone, V3, P50, DOI 10.1016/S1098-3597(01)90069-9
[9]  
Guirguis MS, 2001, J PHARM PHARM SCI, V4, P1
[10]   Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat [J].
Harirforoosh, S ;
Jamali, F .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2005, 83 (01) :85-90